- Home
- BRNS vs DXR Comparison
BRNS vs DXR Comparison
Compare BRNS & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- DXR
- Stock Information
- Founded
- BRNS 2016
- DXR 1970
- Country
- BRNS United Kingdom
- DXR United States
- Employees
- BRNS N/A
- DXR N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- BRNS Health Care
- DXR Health Care
- Exchange
- BRNS Nasdaq
- DXR Nasdaq
- Market Cap
- BRNS 48.3M
- DXR 46.9M
- IPO Year
- BRNS 2021
- DXR N/A
- Fundamental
- Price
- BRNS $1.17
- DXR $11.01
- Analyst Decision
- BRNS Strong Buy
- DXR Strong Buy
- Analyst Count
- BRNS 1
- DXR 1
- Target Price
- BRNS $3.00
- DXR $25.00
- AVG Volume (30 Days)
- BRNS 53.0K
- DXR 79.7K
- Earning Date
- BRNS 08-07-2025
- DXR 01-01-0001
- Dividend Yield
- BRNS N/A
- DXR N/A
- EPS Growth
- BRNS N/A
- DXR 86.16
- EPS
- BRNS N/A
- DXR 0.11
- Revenue
- BRNS $14,969,000.00
- DXR $119,714.00
- Revenue This Year
- BRNS N/A
- DXR N/A
- Revenue Next Year
- BRNS N/A
- DXR N/A
- P/E Ratio
- BRNS N/A
- DXR $101.20
- Revenue Growth
- BRNS 1766.46
- DXR N/A
- 52 Week Low
- BRNS $0.64
- DXR $6.55
- 52 Week High
- BRNS $2.92
- DXR $11.38
- Technical
- Relative Strength Index (RSI)
- BRNS 48.60
- DXR 56.79
- Support Level
- BRNS $1.10
- DXR $10.01
- Resistance Level
- BRNS $1.23
- DXR $11.02
- Average True Range (ATR)
- BRNS 0.13
- DXR 0.68
- MACD
- BRNS -0.02
- DXR 0.01
- Stochastic Oscillator
- BRNS 46.15
- DXR 69.19
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.